A Single Dose Escalation Study of Intra-Articular ICM-203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee
Latest Information Update: 09 May 2025
At a glance
- Drugs ICM-203 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors ICM
Most Recent Events
- 01 May 2025 Planned End Date changed from 1 Nov 2026 to 1 Nov 2027.
- 01 May 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.
- 01 May 2025 Planned initiation date changed from 15 Nov 2024 to 15 Nov 2025.